JANUMET

Type: Product
Name: JANUMET
First reported Sep 07 2014 - Updated Sep 07 2014 - 1 reports

Diabetes belt puts the squeeze on US healthcare

You have probably heard of the “Sun Belt,” “ Rust Belt,” and even the “Borscht Belt.” But few people may realize that there is also an area of the country now referred to as the “Diabetes Belt,” stretching across seven states where the disease is at its ... [Published Examiner.com - Sep 07 2014]
First reported Aug 28 2014 - Updated Aug 28 2014 - 1 reports

3 Reasons Merck & Co., Inc.'s Stock Could Fall

If you were lucky enough to time your purchase of Merck ( NYSE: MRK     ) during the heights of the Great Recession, your investment has probably seen a return of 100% or greater. Unfortunately, timing the stock market is practically impossible to do, ... [Published Motley Fool Discussion Boards - Aug 28 2014]
First reported Aug 20 2014 - Updated Aug 20 2014 - 1 reports

MannKind Corporation: Back To The Fundamentals

Summary The collaboration agreement with Sanofi looks far more attractive upon further review. MannKind should be able to shed the "story stock" label in relatively short order and become less susceptible to the scurrilous attacks that have been common ... [Published Seeking Alpha - Aug 20 2014]
First reported Aug 15 2014 - Updated Aug 15 2014 - 1 reports

Byetta Lawsuit News: Bernstein Liebhard LLP Notes British Columbia's Recent Decision to Discontinue Incretin Mimetic Drug Coverage from PharmaCare Program

Healthcare regulators in British Columbia have stopped patient coverage of a diabetes drug now involved in hundreds of Byetta lawsuits (http://www.byettalawsuit.com/) as well as several other medications, Bernstein Liebhard LLP reports.According to a ... [Published Digital Journal - Aug 15 2014]
First reported Aug 05 2014 - Updated Aug 05 2014 - 1 reports

Merck & Co posts net profit of $2,004 million in Q2

Merck & Co has registered strong growth in profits during the second quarter ended June 2014 despite lower sales. Its net profit increased by 121 per cent to $2,004 million from $906 million in the corresponding period of last year. However, its net sales ... [Published PharmaBiz - Aug 05 2014]
First reported Jul 12 2014 - Updated Jul 12 2014 - 1 reports

Merck seeks to settle patent row with Glenmark

In the long-winding patent battle on a widely-prescribed diabetes drug, Januvia (sitagliptin), multinational company Merck (MSD) has sought a settlement to end the dispute with generic company, Glenmark on the blockbuster drug. Last year, US-based Merck's ... [Published Times of India - Jul 12 2014]
First reported Apr 30 2014 - Updated Apr 30 2014 - 1 reports

Merck & Co net earnings moves up by 7% in Q1

Merck & Co has reported net profit growth of 7 per cent during the first quarter ended March 2014 to $1,705 million from $1,593 million in the corresponding period of last year due to lower R&D expenditure and other costs. Its net sales, however, declined ... [Published PharmaBiz - Apr 30 2014]
First reported Apr 08 2014 - Updated Apr 08 2014 - 1 reports

Why Big Pharma May Not Be Cashing in on Medical Marijuana

Source: Thinkstock Prohibition against marijuana seems to be soon nearing an end, partially motivated by Colorado’s tax windfall since its passage of Amendment 64 , reporting over $3.5 million in revenue for February from recreational and medical ... [Published Wall St. Cheat Sheet - Apr 08 2014]

Quotes

...While other companies have had success buying clinical-stage hepatitis C drugs -- just look at Gilead Sciences " $11 billion purchase of Pharmasset, which yielded the now-blockbuster drug Sovaldi -- Idenix's pipeline has been riddled with disappointments throughout the years."
"We are not surprised by British Columbia's recent decision to discontinue coverage of incretin mimetics from their prescription drug program, as our Firm's lawyers continue to hear from individuals who allegedly developed pancreatic cancer and other serious injuries due to use of Januvia and Byetta" says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective medical devices and drugs...
...Justice AK Pathak said in an order accessed by TOI: "The senior counsel for the defendant states that the defendant has no objection if the matter is referred to mediation centre, as defendant is also keen to settle the matter amicably. Application is allowed"
...the plaintiffs and defendants update the judge on the progress of the litigation and any problems that have developed," said Resource4thePeople. "We will monitor these developments and continue to update consumers who are following this litigation or are considering seeking compensation in connection with these allegations." The latest figures*** provided by the U S Judicial Panel for Multidistrict Litigation shows that there are now 163 cases in the multidistrict litigation...

More Content

All (14) | News (12) | Reports (0) | Blogs (2) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Diabetes belt puts the squeeze on US healthcare [Published Examiner.com - Sep 07 2014]
3 Reasons Merck & Co., Inc.'s Stock Could Fall [Published Motley Fool Discussion Boards - Aug 28 2014]
MannKind Corporation: Back To The Fundamentals [Published Seeking Alpha - Aug 20 2014]
Byetta Lawsuit News: Bernstein Liebhard LLP Not... [Published Digital Journal - Aug 15 2014]
Merck & Co posts net profit of $2,004 million i... [Published PharmaBiz - Aug 05 2014]
Merck seeks to settle patent row with Glenmark [Published Times of India - Jul 12 2014]
Merck & Co net earnings moves up by 7% in Q1 [Published PharmaBiz - Apr 30 2014]
Why Big Pharma May Not Be Cashing in on Medical... [Published Wall St. Cheat Sheet - Apr 08 2014]
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - Mar 27 2014]
Januvia Pancreatic Cancer Allegations Help: Res... [Published PRWeb - Feb 27 2014]
Januvia Pancreatic Cancer Allegations Alert: Re... [Published PRWeb - Jan 19 2014]
TrialNetworks Welcomes Global Pharmaceutical In... [Published PRWeb - Jan 16 2014]
Byetta Pancreatic Cancer Allegations Attorneys:... [Published PRWeb - Dec 19 2013]
Delhi High Court not to grant interim relief to... [Published Topnews.in - Apr 05 2013]
1
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Why Big Pharma May Not Be Cashing in on Medical... [Published Wall St. Cheat Sheet - Apr 08 2014]
Source: Thinkstock Prohibition against marijuana seems to be soon nearing an end, partially motivated by Colorado’s tax windfall since its passage of Amendment 64 , reporting over $3.5 million in revenue for February from recreational and medical ...
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - Mar 27 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.